Total Payments
$5.5M
2024 Payments
$1.1M
Companies
45
Transactions
5,388
Payment Breakdown by Category
Other$3.8M (68.8%)
Consulting$1.0M (18.7%)
Travel$510,050 (9.3%)
Food & Beverage$104,068 (1.9%)
Research$49,303 (0.9%)
Education$21,236 (0.4%)
Gifts$89.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.6M | 1,227 | 65.8% |
| Consulting Fee | $1.0M | 290 | 18.7% |
| Travel and Lodging | $510,050 | 2,272 | 9.3% |
| Honoraria | $129,296 | 38 | 2.4% |
| Food and Beverage | $104,068 | 1,461 | 1.9% |
| Unspecified | $49,303 | 63 | 0.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $28,379 | 13 | 0.5% |
| Education | $21,236 | 20 | 0.4% |
| Grant | $3,035 | 2 | 0.1% |
| Gift | $89.00 | 2 | 0.0% |
Payments by Type
General
$5.4M
5,325 transactions
Research
$49,303
63 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $705,627 | 683 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $663,443 | 559 | $0 (2024) |
| ABBVIE INC. | $547,094 | 478 | $0 (2024) |
| ITI, Inc. | $450,434 | 352 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $356,940 | 425 | $0 (2024) |
| Allergan, Inc. | $355,892 | 433 | $0 (2021) |
| Axsome Therapeutics, Inc. | $308,118 | 283 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $293,953 | 292 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $240,774 | 333 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $164,050 | 154 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1.1M | 990 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($164,050) |
| 2023 | $1.1M | 1,041 | ITI, Inc. ($168,249) |
| 2022 | $851,287 | 806 | ITI, Inc. ($156,488) |
| 2021 | $593,712 | 514 | AbbVie Inc. ($114,956) |
| 2020 | $386,603 | 325 | Allergan, Inc. ($105,113) |
| 2019 | $591,552 | 669 | Teva Pharmaceuticals USA, Inc. ($132,791) |
| 2018 | $532,108 | 582 | Allergan Inc. ($118,751) |
| 2017 | $346,743 | 461 | Alkermes, Inc. ($122,741) |
All Payment Transactions
5,388 individual payment records from CMS Open Payments — Page 1 of 216
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,489.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,489.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,074.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,074.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,913.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,419.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $774.33 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/19/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $324.90 | General |
| Category: CNS | ||||||
| 12/19/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $173.47 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/19/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $33.60 | General |
| Category: CNS | ||||||
| 12/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,120.00 | General |
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $745.43 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $569.53 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $102.83 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,600.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $241.98 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $241.98 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.19 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $128.55 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $128.54 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $108.40 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | Cash or cash equivalent | $24.50 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate | Arbor Pharmaceuticals, Inc. | $29,237 | 7 |
| AR19.004 | ARBOR PHARMACEUTICALS, INC. | $7,250 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE- AND PLACEBO-CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF OPC-64005 IN THE TREATMENT OF ADULT ATTENTION-DEFICITHYPERACTIVITY DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,495 | 5 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | Supernus Pharmaceuticals, Inc. | $3,001 | 20 |
| Assessment of Efficacy and Safety of SPN-810 for the Treatment of Impulsive Aggression IA in Adolescent Subjects with Attention DeficitHyperactivity Disorder ADHD in Conjunction with Standard ADHD Treatment | Supernus Pharmaceuticals, Inc. | $1,503 | 11 |
| An Open-Label, Single-Dose Pharmacokinetic Study of ADZENYS XR ODT in Male and Female Children 4 to Less Than 6 Years of Age With Attention-Deficit/Hyperactivity Disorder (ADHD) | Neos Therapeutics, LP | $1,345 | 7 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,075 | 6 |
| AR19.004 | Arbor Pharmaceuticals, Inc. | $762.13 | 1 |
| Functional Neuroimaging Study to Evaluate the Treatment Effect of SPN-810 Extended-Release Molindone on Impulsive Aggression IA in Patients with Attention-DeficitHyperactivity Disorder ADHD in Conjunction with Standard ADHD Treatment | Supernus Pharmaceuticals, Inc. | $631.49 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $2.83 | 1 |
About Dr. Andrew Cutler, MD
Dr. Andrew Cutler, MD is a Psychiatry healthcare provider based in Lakewood Ranch, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063476125.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Cutler, MD has received a total of $5.5M in payments from pharmaceutical and medical device companies, with $1.1M received in 2024. These payments were reported across 5,388 transactions from 45 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($3.6M).
Ad
Practice Information
- Specialty Psychiatry
- Location Lakewood Ranch, FL
- Active Since 04/14/2006
- Last Updated 03/07/2023
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1063476125
Products in Payments
- VRAYLAR (Drug) $892,297
- CAPLYTA (Drug) $614,484
- AUSTEDO (Drug) $486,372
- INGREZZA (Drug) $292,138
- Auvelity (Drug) $285,585
- REXULTI (Drug) $273,581
- LYBALVI (Drug) $248,220
- ARISTADA (Drug) $243,416
- SPRAVATO (Drug) $153,708
- QELBREE (Drug) $144,092
- Aristada 441 mg (Drug) $136,266
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $100,345
- LATUDA (Drug) $96,567
- NUPLAZID (Drug) $92,115
- UZEDY (Drug) $80,900
- AZSTARYS (Drug) $74,351
- Trintellix (Drug) $73,734
- TRINTELLIX (Drug) $71,350
- Qelbree (Drug) $63,202
- COBENFY (Drug) $46,465
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.